Abstract PS5-07-12: Opt-pembro: a phase III randomized trial of adjuvant pembrolizumab omission in patients with early-stage triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemo-immunotherapy - 2026
Paper published in a journal (Scientific congresses and symposiums)
Abstract PS5-07-12: Opt-pembro: a phase III randomized trial of adjuvant pembrolizumab omission in patients with early-stage triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemo-immunotherapy
Ribeiro, J. M.; Duhoux, F.; Romano, E.et al.
2026 • In Clinical Cancer Research, 32 (4_Supplement), p. 5-07-12-PS5-07-12
Gonçalves, A.; Medical Oncology Department, Institut Paoli-Calmette, Marseille, FRANCE
Punie, K.; Department of Medical Oncology, ZAS Hospitals, Antwerp, FRANCE
Mouret-Reynier, M.; Medical Oncology Department, Centre Jean Perrin, Clermont-Ferrand, FRANCE
Fontaine, C.; Department of Medical Oncology, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, BELGIUM
Bailleux, C.; Medical Oncology Department, Centre Antoine Lacassagne, Nice, FRANCE
Naert, E.; Department of Medical Oncology, Ghent University Hospital, Ghent, BELGIUM
Corbaux, P.; Medical Oncology Department, Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, FRANCE
Derouane, F.; Medical Oncology Department, UZ Leuven, Leuven, BELGIUM
Leheurteur, M.; Medical Oncology Department, Centre Henri Becquerel, Rouen, FRANCE
Jacquet, E.; Medical Oncology Department, University of Franche Comte, FEMTO-ST Institute, CNRS, Besançon, FRANCE
Robert, M.; Medical Oncology Department, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, FRANCE
Lemoine, A.; Medical Oncology Department, Institut Godinot, Paris, FRANCE
Robinson, T.; Medical Oncology Department, Bristol Haematology and Oncology Centre, Bristol, UNITED KINGDOM
Salgado, R.; Department of Pathology, GZA-ZNA Hospitals, Division of Research, Peter Mac Callum Cancer Centre, Melbourne, Australia, Antwerp, BELGIUM
Van Bockstaele, M.; Pathology Department, University Clinics St-Luc, Brussels, BELGIUM
Lambertini, M.; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, ITALY
Tillaux, S.; Service de Biostatistique et d'Epidémiologie, Oncostat Inserm U1018, Université Paris-Saclay, Equipe, Institute Gustave Roussy, Paris, FRANCE
Sara, T.; Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA
Partridge, A.; Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA
Carrey, L.; Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Pilger, K.; Clinical Trial Center, Cliniques universitaires Saint-Luc, Brussels, BELGIUM
Lemonier, J.; Unicancer Research Governance, UNICANCER, Paris, FRANCE
Mardinian, S.; UCBG – French Breast Cancer Intergroup, UNICANCER, Paris, FRANCE
Mijonnet, S.; UCBG – French Breast Cancer Intergroup, UNICANCER, Paris, FRANCE
Clement-Bidard, F.; Department of Medical Oncology, Institut Curie, Paris, FRANCE
Bachelot, T.; Medical Oncology Department, Centre Léon Bérard, Lyon, FRANCE
Ines, V.; Cancer Survivorship Group, INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Institute Gustave Roussy, Paris, FRANCE.
Michiels, S.; Service de Biostatistique et d'Epidémiologie, Oncostat Inserm U1018, Université Paris-Saclay, Equipe, Institute Gustave Roussy, Paris, FRANCE
Olivier, T.; Medical Oncology Department, Centre Léon Bérard, Lyon, FRANCE
Abstract PS5-07-12: Opt-pembro: a phase III randomized trial of adjuvant pembrolizumab omission in patients with early-stage triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemo-immunotherapy
